XIENCE V India: XIENCE V Everolimus Eluting Coronary Stent System (EECSS) India Post-Marketing Registry
Phase 4
Completed
- Registration Number
- CTRI/2008/091/000213
- Lead Sponsor
- Abbott Vascular
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 1000
Inclusion Criteria
The patient agrees to participate in this study by signing the EC approved informed consent form. Alternatively, the patient's legally authorized representative agrees to the patient's participation in this study and signs the informed consent form
Exclusion Criteria
The inability to obtain an informed consent is an exclusion criterion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Composite rate of cardiac death and any myocardial infarction.Timepoint: 1 year;Stent thrombosis rates as defined by Academic Research Consortium (ARC)Timepoint: Annually through to 5 years
- Secondary Outcome Measures
Name Time Method